Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
Imvax has raised $29.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in January 2025.
Imvax's investors include Invus, Magnetar Capital, Ziff Capital Partners, TLP Investment Partners, WILD Group Management.
Imvax is headquartered in Philadelphia, United States.
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
Imvax is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Imvax — Funding & Investors." VCBacked, January 29, 2025, https://www.vcbacked.co/company/imvax. Accessed September 30, 2026.
VCBacked. (2025). Imvax — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/imvax
{{cite web |title=Imvax — Funding & Investors |url=https://www.vcbacked.co/company/imvax |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated